BioArctic: Lecanemab receives priority review status in Japan – Press Release

[ad_1]

STOCKHOLM, Jan. 30, 2023 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™) in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Lecanemab is an anti-amyloid-β (Aβ) protofibril[1] antibody for treatment of Alzheimer’s disease (AD). Priority Review in Japan is granted to new medicines recognized as having high medical utility for serious diseases, and once designated for Priority Review, the target total review period is shortened.

In Japan, Eisai submitted the manufacturing and marketing approval for lecanemab to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023. This application is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.

Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD. As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease. The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, the results of the Clarity AD study were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference and simultaneously published in the New England Journal of Medicine, a peer-reviewed medical journal.

In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. In Europe, Eisai submitted a…

[ad_2]